Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 16/8/2018
SIETES contiene 92469 citas

 
 
 1 a 20 de 238 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Ramaekers JG. Driving under the influence of cannabis. An increasing public health concern. JAMA 2018;319:10 de abril. [Ref.ID 102668]
2. Cita con resumen
Gorelick DA. The effects of cannabis among adults with chronic pain. Ann Intern Med 2018;168:525. [Ref.ID 102602]
3.Enlace a cita original Cita con resumen
Baket T, Datta P, Rewers-Felkins K, Thompson H, Kallem RR, Hale TW. Transfer of inhaled cannabis into human breast milk. Obstet Gynecol 2018;131:783-8. [Ref.ID 102575]
4. Cita con resumen
Nugent SM, Morasco BJ, O'Neil ME, Freeman M, Low A, Kondo K, Elven C, Zakher B, Motu'apuaka M, Paynter R, Kansagara D. The effects of cannabis among adults with chronic pain and an overview of general harms: a systematic review. Ann Intern Med 2017;167:319-31. [Ref.ID 102022]
5. Cita con resumen
Ford BM, Tai S, Fantegrossi WE, Prather PL. Synthetic pot: not your grandfathers marijuana. Trends Pharmacol Sci 2017;38:257-76. [Ref.ID 101989]
6. Cita con resumen
Anónimo. Brazil issues first license for sale of cannabis-based drug. DIA Daily 2017:1. [Ref.ID 101349]
7. Cita con resumen
Anónimo. Cannabis and cannabinoids. Med Lett Drugs Ther 2016;58:97-8. [Ref.ID 100510]
8. Cita con resumen
Wise J. Skunk-like cannabis may damage white matter in the brain, study shows. BMJ 2015;351:h6417. [Ref.ID 99733]
9. Cita con resumen
McCall C. Momentum grows for medical use of cannabis. Lancet 2015;386:1615-6. [Ref.ID 99633]
10. Cita con resumen
Ware MA, Wang T, Shapiro S, Collet J-P. Cannabis for the management of pain: assessment of safety study (COMPASS). The Journal of Pain 2015;16:1233-42. [Ref.ID 99551]
11. Cita con resumen
Friedman D, Devinsky O. Cannabinoids in the treatment of epilepsy. N Engl J Med 2015;373:1048-58. [Ref.ID 99459]
12. Cita con resumen
Pryce G, Baker D. Cannabinoids fail to show evidence of slowing down the progression of multiple sclerosis. Evid Based Med 2015;20:124. [Ref.ID 99261]
14. Cita con resumen
Cao C, Li Y, Liu H, Bai G, May J, Lin X, Sutherland K, Nabar N, Cai J. The potential therapeutic effects of THC on Alzheimer’s disease. Journal of Alzheimer's Disease 2014;42:973-84. [Ref.ID 97862]
15. Cita con resumen
Wilkinson ST, D'Souza DC. Problems with the medicalization of marijuana. JAMA 2014;311:2377-8. [Ref.ID 97599]
16.Enlace a cita originalTiene citas relacionadas
Rezkalla S, Kloner RA. Recreational marijuana use: is it safe for your patient?. Journal of the American Heart Association 2014;3:e000904. [Ref.ID 97482]
17.Enlace a cita originalTiene citas relacionadas
Jouanjus E, Lapeyre-Mestre M, Micallef J, The French association of the regional abuse and dependence monitoring centres (CEIP-A) working group on cannabis complications. Cannabis use: signal of increasing risk of serious cardiovascular disorders. Journal of the American Heart Association 2014;3:e000638. [Ref.ID 97472]
18.Enlace a cita original Cita con resumen
Yadav V, Bever Jr C, Bowen J, Bowling A, Weinstock-Guttman B, Cameron M, Bourdette D, Gronseth GS, Narayanaswami P. Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis. Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2014;82:1083-92. [Ref.ID 97315]
19. Cita con resumen
Klumpers LE, Fridberg M, de Kam ML, Little PB, Jensen NO, Kleinloog HD, Elling CE, van Gerven JM. Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects. Br J Clin Pharmacol 2013;76:846-57. [Ref.ID 96629]
20. Cita con resumen
Gunderson EW. Synthetic cannabinoids: a new frontier of designer drugs. Ann Intern Med 2013;159:563-4. [Ref.ID 96386]
Seleccionar todas
 
 1 a 20 de 238 siguiente >>